Tag: BioScrip

  • Healthcare gainers: Mallinckrodt PLC (NYSE:MNK), Novavax (NASDAQ:NVAX), BioScrip Inc (NASDAQ:BIOS), Zogenix (NASDAQ:ZGNX)

    Mallinckrodt PLC (NYSE:MNK) was the recipient of some unusual options trading activity on Tuesday. Traders acquired 7,891 put options on the stock, American Banking News.com reports. This is an increase of 1,642% compared to the average daily volume of 453 put options. Mallinckrodt PLC (NYSE:MNK) shares after opening at $61.31 moved to $64.32 on last trade day and at the end of the day closed at $64.23. Company price to sales ratio in past twelve months was calculated as 1.36 and price to cash ratio as 12.98. Mallinckrodt PLC (NYSE:MNK) showed a positive weekly performance of 2.62%.

    Novavax, Inc. (NASDAQ:NVAX) announced that Stanley C. Erck, President and Chief Executive Officer, will present at 13 Annual Needham Healthcare Conference on Apr. 9, 2014 at 12:10 pm ET in New York City at Westin Grand Central Hotel.Novavax, Inc. (NASDAQ:NVAX) shares advanced 5.37% in last trading session and ended the day on $4.32. return on equity ratio is recorded as -41.40% and its return on assets is -34.10%. Novavax, Inc. (NASDAQ:NVAX) yearly performance is 68.75%.

    BioScrip Inc (NASDAQ:BIOS) up 6.7% after stock was named as a stock pick and a potential takeover target by Oscar Schafer while speaking on CNBC BioScrip Inc (NASDAQ:BIOS) shares moved up 5.81% in last trading session and was closed at $7.19 while trading in range of $ 7.02 – $7.44 – BioScrip Inc (NASDAQ:BIOS) year to date (YTD) performance is -2.84%.

    Zogenix, Inc. (NASDAQ:ZGNX) filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by Governor Deval Patrick, which prohibits the prescribing and dispensing of the Company’s prescription pain product that was approved by the U.S. Food and Drug Administration (FDA). Zogenix, Inc. (NASDAQ:ZGNX) weekly performance is -10.38%. On last trading day company shares ended up $2.59. Zogenix, Inc. (NASDAQ:ZGNX) distance from 50-day simple moving average (SMA50) is -34.23%. Analysts mean target price for the company is $5.73.